FDA ad­comm votes in fa­vor of Geron's ane­mia drug for can­cer pa­tients de­spite ques­tions on risk

Mem­bers of the FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee vot­ed 12 to 2 on Thurs­day that the ben­e­fits of Geron’s ime­tel­stat out­weigh safe­ty risks for the treat­ment of cer­tain ane­mic myelodys­plas­tic syn­drome (MDS) pa­tients who are de­pen­dent on blood trans­fu­sions.

While reg­u­la­tors raised con­cerns around cas­es of cy­tope­nia, or low lev­els of white blood cells or platelets, ad­vi­so­ry com­mit­tee mem­bers said they were con­fi­dent that the risks ap­pear man­age­able. The FDA not­ed on Thurs­day that there was a “no­tably high­er” in­ci­dence of neu­trope­nia and throm­bo­cy­tope­nia in the ime­tel­stat arm of a Phase III tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER